Innate immunity in resistance to HIV infection

Journal of Infectious Diseases

Volumn 202, Issue SUPP.3, 2010, Pages

  Biasin, Mara ^a   Clerici, Mario ^b   Piacentini, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; AMYLOID A PROTEIN; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTOKINE; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 22; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PEROXIREDOXIN 2; POLYINOSINIC POLYCYTIDYLIC ACID; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; SERUM AMYLOID A; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; CELL MEDIATED CYTOTOXICITY; CONFERENCE PAPER; CYTOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION RESISTANCE; INFECTION SENSITIVITY; INNATE IMMUNITY; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIREMIA; VIRUS INFECTIVITY; VIRUS PATHOGENESIS; VIRUS REPLICATION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY;

CYTIDINE DEAMINASE; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; KILLER CELLS, NATURAL; SERUM AMYLOID A PROTEIN; TOLL-LIKE RECEPTORS;

EID: 78049433762     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655965     Document Type: Conference Paper

References (25)

1. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 7:21-24.
2. Piacentini L, Fenizia C, Naddeo V, Clerici M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 2008; 26(24):3002-3007.
3. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262(1):44-58.
4. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2009; 265(1):110-124.
5. Barton GM. Viral recognition by Toll-like receptors. Semin Immunol 2007; 19(1): 33-40.
6. Biasin M, Piacentini L, Lo Caputo S, et al. TLR activation pathways in HIV-1-exposed seronegative individuals. J Immunol 2010; 184(5):2710-2717.
7. Suy A, Castro P, Nomdedeu M, et al. Immunological profile of heterosexual highly HIV exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis 2007; 196:1191-1201.
8. Wille-Reece U, Flynn BJ, Loré K, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005; 102(42):15190-15194.
9. Browne EP, Littman DR. Myd88 is required for an antibody response to retroviral infection. PLoS Pathog 2009; 5(2):e1000298.
10. Scott-Algara D, Truong LX, Versmisse P, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171(11):5663-5667.
11. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006; 120(2):138-146. (Pubitemid 44080673)
12. Ballan WM, Vu BA, Long BR, et al. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. Clin Vaccine Immunol 2008; 15(1):120-130.
13. Jennes W, Verheyden S, Demanet C, et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177(10):6588-6592.
14. Boulet S, Sharafi S, Simic N. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008; 22(5):595-599.
15. Ravet S, Scott-Algara D, Bonnet E, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109(10):4296-4305.
16. Iannello A, Debbeche O, Samarani S, Ahmad A. Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination. J Leukoc Biol 2008; 84(1):27-49. (Pubitemid 351960278)
17. Choi EI, Reimann KA, Letvin NL. In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J Virol 2008; 82(13):6758-6761.
18. Missé D, Yssel H, Trabattoni D, et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 2007; 178(1):407-415.
19. Kramer HB, Lavender KJ, Qin L. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog 2010; 6(5):e1000893.
20. Biasin M, Piacentini L, Lo Caputo S, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007; 195(7):960-964.
21. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005; 79(17):11513-11516.
22. Vázquez-Pérez JA, Ormsby CE, Hernández-Juan R, Torres KJ, Reyes-Terán G. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 2009; 6:23.
23. Reddy K, Winkler CA, Werner L, et al. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 2010; 24(2):195-204.
24. Smith JL, Bu W, Burdick RC, Pathak VK. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci 2009; 30(12):638-646.
25. Sui Y, Zhu Q, Gagnon S, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 2010; 107(21):9843-9848.